CONSIDERATIONS FOR
CSU MANAGEMENT

EACCI/GA2LEN/EuroGuiDerm/
WAO Guidelines suggest to treat
chronic urticaria until
it is
resolved. At 90% consensus,
the guidelines recommend
aiming at
complete symptom
control in urticaria, considering
the safety and the quality
of life
of each individual patient as much as possible1,2:

Complete control of signs
and symptoms of CSU1

Treating as much as needed
and as little as possible1

AAAAI/ACAAI and EAACI/
GA²LEN/EuroGuiDerm/APAAACI
Guidelines, recommend a step-wise approach to treatment1,2

aUp to 5 mg/kg body weight.
b300 mg every 4 weeks. If needed, increase dose and/or shorten interval (up to 600 mg every 2 weeks).

Despite the use of current
therapies,
some patients are
not adequately controlled 3,4

AAAAI, American Academy of Allergy, Asthma & Immunology; ACAAI, American College of Allergy, Asthma & Immunology; APAAACI, Asia Pacific Association of Allergy, Asthma, and Clinical Immunology; CSU, chronic spontaneous urticaria; EAACI, European Academy of Allergology and Clinical Immunology; GA²LEN, Global Allergy and Asthma European Network; WAO, World Allergy Organization.


References: 1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021. doi:10.1111/all.15090. Epub ahead of print. 2. Bernstein JA, Lang D, Khan D, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5): 1270-1277. 3. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Br J Dermatol. 2016;175(6):1153-1165. 4. Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. Ann Allergy Asthma Immunol. 2020;124(1):2-12.